Cargando…

Transarterial Radioembolization (TARE) Agents beyond (90)Y-Microspheres

Liver malignancies, either primary tumours (mainly hepatocellular carcinoma and cholangiocarcinoma) or secondary hepatic metastases, are a major cause of death, with an increasing incidence. Among them, hepatocellular carcinoma (HCC) presents with a dark prognosis because of underlying liver disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouvry, C., Palard, X., Edeline, J., Ardisson, V., Loyer, P., Garin, E., Lepareur, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330886/ https://www.ncbi.nlm.nih.gov/pubmed/30687734 http://dx.doi.org/10.1155/2018/1435302

Ejemplares similares

(188)Re-SSS Lipiodol Radioembolization in HCC Patients: Results of a Phase 1 Trial (Lip-Re-01 Study)
por: Garin, Etienne, et al.
Publicado: (2023)

Clinical Results of Transarterial Radioembolization (TARE) with Holmium-166 Microspheres in the Multidisciplinary Oncologic Treatment of Patients with Primary and Secondary Liver Cancer
por: Drescher, Robert, et al.
Publicado: (2023)

Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres
por: Garin, Etienne, et al.
Publicado: (2015)

A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma
por: Zhen, Yanhua, et al.
Publicado: (2019)

Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma
por: Chan, Hui-Wen, et al.
Publicado: (2022)

Inter-observer variability of (90)Y PET/CT dosimetry in hepatocellular carcinoma after glass microspheres transarterial radioembolization
por: Meyers, Nicolas, et al.
Publicado: (2020)

Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience
por: Kim, Alexander Y., et al.
Publicado: (2016)

Transarterial Radioembolization (TARE) with (131) Iodine-Lipiodol for Unresectable Primary Hepatocellular Carcinoma: Experience from a Tertiary Care Center in India
por: Patel, Aakash, et al.
Publicado: (2021)

Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study
por: Katharina Ingenerf, Maria, et al.
Publicado: (2021)

Lobar Hepatocellular Carcinoma with Ipsilateral Portal Vein Tumor Thrombosis Treated with Yttrium-90 Glass Microsphere Radioembolization: Preliminary Results
por: Pracht, M., et al.
Publicado: (2013)

Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma
por: Kallini, Joseph Ralph, et al.
Publicado: (2016)

Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma
por: Palard, Xavier, et al.
Publicado: (2017)

Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments
por: Cappelli, Alberta, et al.
Publicado: (2014)

Imaging evaluation following transarterial radioembolization with yttrium-90 microspheres downstaging hepatocellular carcinoma: the first case in China
por: Li, Xiaoming, et al.
Publicado: (2023)

Evaluation of the pharmacokinetics, dosimetry, and therapeutic efficacy for the α-particle-emitting transarterial radioembolization (αTARE) agent [(225)Ac]Ac-DOTA-TDA-Lipiodol(®) against hepatic tumors
por: Josefsson, Anders, et al.
Publicado: (2023)

High impact of macroaggregated albumin‐based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90)Y‐loaded glass microsphere radioembolization
por: Garin, Etienne, et al.
Publicado: (2016)

Internal dosimetry for radioembolization therapy with Yttrium‐90 microspheres
por: Fallahpoor, Maryam, et al.
Publicado: (2017)

Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib
por: Teyateeti, Ajalaya, et al.
Publicado: (2021)

Transarterial radioembolization with Yttrium-90: current status and future prospects
por: Yang, Hua-Yu, et al.
Publicado: (2020)

Gastrectomy for the treatment of refractory gastric ulceration after radioembolization with (90)Y microspheres
por: Yim, Sun Young, et al.
Publicado: (2014)

A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study
por: Lam, Marnix, et al.
Publicado: (2022)

Combining Transarterial Radioembolization (TARE) and CT-Guided High-Dose-Rate Interstitial Brachytherapy (CT-HDRBT): A Retrospective Analysis of Advanced Primary and Secondary Liver Tumor Treatment
por: Fleckenstein, Florian Nima, et al.
Publicado: (2021)

Yttrium-90 Microsphere Radioembolization for Treatment of Lung Cancer Hepatic Metastases
por: Gaba, Ron C., et al.
Publicado: (2012)

Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate Cancer
por: Bunck, Alexander C., et al.
Publicado: (2017)

Standardizing SPECT/CT dosimetry following radioembolization with yttrium-90 microspheres
por: Kim, S. Peter, et al.
Publicado: (2021)

Assessment of Treatment Response Following Yttrium-90 Transarterial Radioembolization of Liver Malignancies
por: Adcock, Charles S, et al.
Publicado: (2018)

Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer
por: Puleo, Luciana, et al.
Publicado: (2022)

Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement
por: Şener, Nur, et al.
Publicado: (2023)

Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study
por: Barakat, Elie, et al.
Publicado: (2021)

Combining Immunotherapy with Transarterial Radioembolization
por: Balaban Genc, Zeynep Ceren, et al.
Publicado: (2023)

Feasibility of imaging (90)Y microspheres at diagnostic activity levels for hepatic radioembolization treatment planning
por: Kunnen, Britt, et al.
Publicado: (2020)

Transarterial radioembolization: a systematic review on gaining control over the parameters that influence microsphere distribution
por: Snoeijink, T. J., et al.
Publicado: (2023)

Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization
por: Lenoir, Laurence, et al.
Publicado: (2012)

Advances in SPECT for Optimizing the Liver Tumors Radioembolization Using Yttrium-90 Microspheres
por: Roshan, Hoda Rezaei, et al.
Publicado: (2015)

Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study
por: Maleux, Geert, et al.
Publicado: (2023)

(68)Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE)
por: Ingenerf, Maria, et al.
Publicado: (2021)

Clinical and Laboratory Toxicity after Intra-Arterial Radioembolization with (90)Y-Microspheres for Unresectable Liver Metastases
por: Smits, Maarten L. J., et al.
Publicado: (2013)

Contralateral Liver Hypertrophy and Oncological Outcome Following Radioembolization with (90)Y-Microspheres: A Systematic Review
por: Birgin, Emrullah, et al.
Publicado: (2020)

Novel (175)Yb-Poly (L-Lactic Acid) Microspheres for Transarterial Radioembolization of Unrespectable Hepatocellular Carcinoma
por: Jamre, Mina, et al.
Publicado: (2019)

Facile Preparation of Samarium Carbonate-Polymethacrylate Microspheres as a Neutron-Activatable Radioembolic Agent for Hepatic Radioembolization
por: Wong, Yin How, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hdm6tu1km0gr5pfvpnt60u22gf